HomeCompareMCRPF vs ARCC

MCRPF vs ARCC: Dividend Comparison 2026

MCRPF yields 127.39% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCRPF wins by $26.2K in total portfolio value
10 years
MCRPF
MCRPF
● Live price
127.39%
Share price
$1.57
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$50.7K
Annual income
$32.01
Full MCRPF calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — MCRPF vs ARCC

📍 MCRPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMCRPFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MCRPF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MCRPF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MCRPF
Annual income on $10K today (after 15% tax)
$10,828.03/yr
After 10yr DRIP, annual income (after tax)
$27.21/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, MCRPF beats the other by $26.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MCRPF + ARCC for your $10,000?

MCRPF: 50%ARCC: 50%
100% ARCC50/50100% MCRPF
Portfolio after 10yr
$37.6K
Annual income
$16.58/yr
Blended yield
0.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

MCRPF
No analyst data
Altman Z
0.5
Piotroski
4/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MCRPF buys
0
ARCC buys
13
PoliticianChamberTickerTypeAmountDate
John Fetterman🏛 Senate$ARCC▲ Buy$1,001 - $15,0002025-09-09
John Fetterman🏛 Senate$ARCC▼ Sell$1,001 - $15,0002025-09-04
Ashley Moody🏛 Senate$ARCC▲ Buy$15,001 - $50,0002025-04-04
John Fetterman🏛 Senate$ARCC▲ Buy$1,001 - $15,0002025-02-18
Dave McCormick🏛 Senate$ARCC▲ Buy$250,001 - $500,0002025-01-17
Pete Sessions🏢 House$ARCC▼ Sell$1,001 - $15,0002023-11-01
Pete Sessions🏢 House$ARCC▲ Buy$569.252023-10-06
Pete Sessions🏢 House$ARCC▲ Buy$0 - $1,0002023-10-06
Pete Sessions🏢 House$ARCC▲ Buy$155.922023-08-15
Pete Sessions🏢 House$ARCC▲ Buy$0 - $1,0002023-08-15
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMCRPFARCC
Forward yield127.39%10.65%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%-50%
Portfolio after 10y$50.7K$24.5K
Annual income after 10y$32.01$1.14
Total dividends collected$18.5K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: MCRPF vs ARCC ($10,000, DRIP)

YearMCRPF PortfolioMCRPF Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$17,069$6,369.43$11,373$532.74+$5.7KMCRPF
2$23,345$5,080.49$12,608$279.46+$10.7KMCRPF
3$28,226$3,246.85$13,809$142.90+$14.4KMCRPF
4$32,036$1,834.45$15,042$72.20+$17.0KMCRPF
5$35,251$972.93$16,341$36.27+$18.9KMCRPF
6$38,219$500.27$17,732$18.18+$20.5KMCRPF
7$41,148$253.46$19,231$9.10+$21.9KMCRPF
8$44,156$127.51$20,851$4.55+$23.3KMCRPF
9$47,311$63.94$22,605$2.28+$24.7KMCRPF
10$50,655$32.01$24,504$1.14+$26.2KMCRPF

MCRPF vs ARCC: Complete Analysis 2026

MCRPFStock

MicroPort Scientific Corporation, an investment holding company, manufactures, and markets, and distributes medical devices in the People's Republic of China, North America, Europe, other Asian countries, South America, and internationally. The company's Cardiovascular Devices segment offers products and services for the treatment of coronary artery-related diseases; coronary stents and related delivery systems; and balloon catheters and accessories. Its Orthopedics Devices segment provides reconstructive joints, spine and trauma, and other professional implants and instruments. The company's Cardiac Rhythm Management Business segment offers defibrillators, cardiac resynchronization therapy devices, and pacemakers for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Its Endovascular and Peripheral Vascular Devices segment provides products and services for the interventional treatment of thoracic and abdominal aortic aneurysm, peripheral vascular diseases, aortic dissection, and other endovascular related diseases. The company's Neurovascular Devices segment offers neurovascular therapeutic and access devices for neurovascular diseases. Its Heart Valve Business segment provides VitaFlow Transcatheter aortic valve and delivery system, VitaFlow Liberty Transcatheter aortic valve implantation and retrievable delivery systems, Alwide Plus Balloon Catheter, various transcatheter aortic valve implantation, transcatheter mitral valve, transcatheter tricuspid valve, and surgical valve products. The company's Surgical Robot Business segment designs, develops, and commercializes surgical robots comprising robot ontology, control algorithm, electrical engineering, image-based navigation, and precision imaging. Its Surgical Devices segment researches and develops, manufactures, and sells surgical devices. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, the People's Republic of China.

Full MCRPF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this MCRPF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MCRPF vs SCHDMCRPF vs JEPIMCRPF vs OMCRPF vs KOMCRPF vs MAINMCRPF vs HTGCMCRPF vs GBDCMCRPF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.